Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI

Inclusion Criteria: Patients with acute coronary syndrome (ST-depression in at least 2 leads \> 0,1 mV), or T-wave inversion, with or without elevated myocardial biomarkers (Troponin T oder I), together with typical clinical presentation), treated as follows: * Acute percutaneous revascularization with stent implantation within 48 hours after symptom onset. * Successful acute PCI (residual stenosis \< 30%, TIMI flow \> 2). * Hemodynamic stability * Age 18 - 80 years * Written informed consent * Active contraception in women of childbearing age Exclusion Criteria: * Patients with STEMI (ST elevation in 2 leads above 0,2 mV in lead V1, V2 oder V3 or above 0,1 mV in the other leads) * Necessity of additional PCI in non-infarct vessel at the time of study therapy (multi-vessel PCI in the acute event is possible) * Heart failure (LVEF ≤ 30 %). * Arteriovenous malformation or aneurysms * Active infection (C-reactive protein \> 10 mg/dl), or fever, or diarrhoea within the last 4 weeks * Chronic inflammatory disease * HIV infection or active hepatitis * Neoplastic disease without documented complete remission within the last 5 years * Recent stroke within the last 3 months * Impaired kidney function (creatinin \> 2,5 mg/dl) at the time of treatment * Significant liver disease (GOT \> 2x upper normal value or spontaneous INR \> 1,5. * Hematopoetic disease (anaemia with Hb\< 8.5 mg/dl; thrombocytopenia \< 100.000/µl; splenomegaly * Known allergies to Clopidogrel, Heparin or Abciximab * History of bleeding disorder * GI bleeding within the last 3 months * Major surgery or trauma within the last 2 months * Uncontrolled hypertension * Pregnancy * Mental disability * Previous progenitor cell therapy * Participation in a different clinical trial within the last 30 days